Application | Comment | Organism |
---|---|---|
medicine | enzyme/prodrug combination for selectively inducing apoptosis in lentiviral vector-transduced cells, based on designed variants of human thymidylate kinase that effectively phosphorylate 3'-azido-3'-deoxythymidine. Mechanism involves apoptosis induction via disruption of the inner membrane potential and activation of caspase-3. Low-dose 3'-azido-3'-deoxythymidine administration to non-obese diabetic/severe combined immunodeficiency mice injected with the engineered cells suppresses tumor growth | Homo sapiens |
Protein Variants | Comment | Organism |
---|---|---|
additional information | engineering of enzyme/prodrug combinations for selectively inducing apoptosis in lentiviral vector-transduced cells, based on designed variants of human thymidylate kinase that effectively phosphorylate 3'-azido-3'-deoxythymidine. Recombinant lentiviral vector constructs contain either mutant F105Y of human thymidylate kinase or mutant R16G that additionally displays an exchange of 11 amino acids residues of wild-type with 13 residues from the Escherichia coli orthologue. In addition, they contain human CD19 lacking its cytoplasmic tail | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |